Invitation to a webcast: adapting and acting in response to the Covid-19 crisis
20 April 2020
FOR ANY FURTHER INFORMATION,
PLEASE CONTACT:
communication@medincell.com
Our news
Bringing you the latest!
All news
MedinCell has launched a COVID-19 research initiative based on its experience to formulate long-acting injectable Ivermectin
6 April 2020
MedinCell receives $ 6.4 million grant from Unitaid to fight Malaria
25 March 2020
MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020
13 January 2020
Publication of the activity report and financial information for the first half-year (April – Sept. 2019)
3 December 2019
MedinCell receives $19 million grant for its mdc-WWM program
28 November 2019
MedinCell announces that mdc-CWM progresses as planned
27 September 2019
The MedinCell General Meeting votes to include the “Raison d’être” of the Company in its articles of association
10 September 2019
Press
Communication leader
MedinCell
David Heuzé
david.heuze@medincell.com
+33 (0)6 83 25 21 86
Media
NewCap
Nicolas Merigeau
medincell@newcap.eu
+33 (0)1 44 71 94 94
Investors
Investor Relations
NewCap
Louis-Victor Delouvrier /
Alexia Faure
medincell@newcap.eu
+33 (0)1 44 71 94 94